Summer Street Upgrades Imclone (IMCL) to Buy
More News related to IMCL
- ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
- Notification of Extraordinary General Meetings and Further Changes to Board Composition
- ImClone's (IMCL) Phase 2 Trial of IMC-A12 and IMC-1121B Open for Patient Enrollment
- Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
- Loeb's Third Point Buys Into Starwood (HOT) and Tibco (TIBX), Dumps Yahoo! (YHOO)
Summer Street upgrades Imclone (Nasdaq: IMCL) from Neutral to Buy. Price target $48.
ImClone Systems Incorporated (ImClone) is a biopharmaceutical company that develops a portfolio of targeted biologic treatments designed to address the medical needs of patients with cancer.
Related Categories
UpgradesStocks Mentioned
-0.50Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
